Jubilant Pharma receives ANDA final approval for Doxepin Hydrochloride Capsules

23 Mar 2022 , 01:33 AM

Jubilant Pharmova announced that Jubilant Pharma a material wholly owned subsidiary of the Company through one of its subsidiaries Jubilant Cadista Pharmaceuticals Inc has received Abbreviated New Drug Application ANDA final approval for Doxepin Hydrochloride Capsules 10 mg 25mg 50mg 75mg and 100mg the generic version of Sinequan which is used for the treatment of anxiety depression and other target symptoms of psychoneurosis As on 31 December 2021 Jubilants Pharmaceuticals business had a total of 98 ANDAs for Oral Solids filed in the US of which 61 have been approved and 4 InjectableOpthalmic filings of which 2 have been approved